Frailty and Risk of Serious Infections in Patients With Rheumatoid Arthritis Treated With Biologic or Targeted-Synthetic Disease-Modifying Antirheumatic Drugs.
Namrata SinghLaura S GoldJiha LeeKatherine D WyshamJames S AndrewsUna E MakrisBryant R EnglandMichael D GeorgeJoshua F BakerJeffrey JarvikPatrick J HeagertySiddharth SinghPublished in: Arthritis care & research (2023)
Frailty is an important predictor for the risk of adverse outcomes among patients with RA treated with biologic or targeted-synthetic DMARDs.